A Phase 1a/1b First-in-human Multicenter Study to Assess the Efficacy and Safety of RGT-61159 for Treatment of Patients with Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Go Back to All Clinical Trials

A Phase 1a/1b First-in-human Multicenter Study to Assess the Efficacy and Safety of RGT-61159 for Treatment of Patients with Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Rectal Cancer, Breast Cancer, Cervical Cancer, Esophageal Cancer, Oropharyngeal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic
Age: Between 18 Year(s) - 99 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Histologically confirmed ACC or CRC
2. Must have locally R/R advanced or metastatic disease not amenable to potentially curative surgery or radiotherapy
3. ACC – a fresh tumor biopsy from a lesion not previously irradiated is preferred

You may not be eligible for this study if the following are true:

1. Major surgery or significant traumatic injury within 28 days prior to Cycle 1 Day 1
2. Chemotherapy within 14 days prior to Cycle 1 Day 1
3. Use of nitrosoureas or mitomycin C within 6 weeks prior to Cycle 1 Day 1

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies